Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07740421) titled 'A Prospective, Multicenter, Phase III Clinical Evaluation of the Safety and Efficacy of NH002 as a Contrast Agent Administrated Via Intravenous Bolus Injection and Infusion for Subjects Undergoing Cardiac Echocardiography' on July 28.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).
Primary Sponsor: Trust Bio-sonics, Inc.
Condition:
Cardiac Diseases
Intervention:
Drug: NH002 (Perflutren Lipid Microspheres) Injectable Suspension
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enr...